Genentech expects two advisory committee reviews
Executive Summary
Genentech is hoping for third quarter FDA advisory committee review of Raptiva (efalizumab) for moderate to severe plaque psoriasis in patients 18 and older, firm says during investor meeting March 14. BLA for the recombinant humanized monoclonal antibody was filed by Genentech and XOMA in December. Firm also expects Pulmonary-Allergy Drugs Advisory Committee review of Xolair (omalizumab) for moderate to severe allergic asthma in patients 12 and older ahead of an expected action date on the application by mid-year...
You may also be interested in...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.